Testosterone Samples
Testosterone Samples is reader-supported. We may earn a commission when you start a consult through one of our links — never paid for placement. Full disclosure
Editorial guide · TRT side effects

TRT Side Effects by Formulation 2026: Injection vs Gel vs Patch vs Pellet

Reviewed by GLP1 Samples EditorialFact-checked

TRT side effects come in two categories: systemic effects from elevated testosterone levels (polycythemia, acne, prostate effects, lipid changes, mood fluctuations) and formulation-specific effects from the delivery method (injection-site reactions, gel skin transfer, patch irritation, pellet insertion issues). The systemic profile is roughly equivalent across formulations at properly-dosed steady state — testosterone is testosterone regardless of how you deliver it. The format-specific differences are where most patients see meaningful variation.

The FDA's March 2025 removal of the 2014 cardiovascular black-box warning was a major shift in TRT safety framing. The TRAVERSE trial (NEJM 2023) demonstrated cardiovascular safety in middle-aged and older men with hypogonadism, and the FDA labeling caught up. Cardiovascular safety monitoring (lipid panel quarterly) remains standard of care, but the catastrophic-risk framing of the 2014-2024 era is no longer FDA's position.

This guide covers the side-effect profile common to all TRT, the format-specific effects that differ by delivery method, the practical management decision tree for common issues, and the monitoring cadence that catches problems early.

Most common side effect
Polycythemia (5-15%)
FDA CV black-box
Removed March 2025
Hematocrit check cadence
Quarterly
Gel transfer risk
Real (BBW survives 2025)

Systemic side effects (all TRT formulations)

These effects come from elevated testosterone, not from the delivery method. They apply equally to cypionate injection, gel, patch, pellet, and oral testosterone undecanoate. Frequency varies by individual, dose, and protocol stability.

  • Polycythemia / elevated hematocrit (5-15%). Testosterone stimulates red blood cell production. Quarterly hematocrit monitoring catches it early. Managed with dose reduction, formulation change, or therapeutic phlebotomy.
  • Acne and oily skin (20-30% in first 2-3 months). Common during dose-finding; usually resolves once protocol stabilizes. Topical retinoids and benzoyl peroxide are first-line management.
  • Estrogen-related effects (10-25%). Testosterone aromatizes to estradiol; some patients develop water retention, mood swings, or breast tissue sensitivity. Managed with dose adjustment or aromatase inhibitor (AI) co-therapy in selected patients.
  • Testicular atrophy + reduced sperm production (most patients). TRT suppresses pituitary signaling. HCG co-therapy preserves both testicular volume and spermatogenesis for fertility-prioritizing patients.
  • Mood / energy fluctuations during titration (variable). Especially on weekly injection protocols with significant peak/trough. Stabilizes once protocol is dialed in or moves to flatter dosing schedule.
  • Prostate effects.PSA may rise modestly; BPH symptoms may worsen. Quarterly PSA monitoring; urology workup if PSA rises >1.4 ng/mL in 12 months or absolute >4.0 ng/mL.
  • Lipid changes. Some patients see HDL decrease and LDL increase modestly. Quarterly lipid monitoring; statin or dietary intervention as indicated.
  • Sleep apnea worsening. TRT can worsen pre-existing sleep apnea. Severe untreated sleep apnea is a contraindication; treated apnea is fine.

Injection-specific side effects (cypionate, enanthate)

Beyond systemic effects, intramuscular and subcutaneous testosterone injections add:

  • Peak/trough mood and energy variability (with weekly dosing).Weekly 200mg cypionate produces plasma peak around day 2-3 and trough around day 7. Some patients tolerate the curve fine; others experience energy/mood fluctuations tracking the curve. Fix: split to twice-weekly (Mon/Thu canonical, 100mg each) or daily SubQ (typically 25-30mg) — flattens the curve dramatically.
  • Injection-site soreness. Mild for SubQ (27G insulin needle into abdominal/thigh fat); more pronounced for IM (1.5-inch needle into glute/thigh muscle). SubQ has largely replaced IM as the modern TRT default for this reason.
  • Rare injection-site infection. Proper sterile technique (alcohol prep, never re-use needles, sharps container disposal) prevents virtually all cases.
  • Cough or shortness of breath immediately after injection (very rare).Pulmonary oil microembolism — a rare reaction to the oil-based vehicle of cypionate or enanthate. Self-limiting, but report any episode to your prescriber.

Gel-specific side effects (AndroGel, Testim, Vogelxo)

Topical testosterone gels add:

  • Skin transfer to family members (BLACK-BOX WARNING — survived 2025 label change).Skin-to-skin contact between a gel-applying patient and a partner, child, or pet can transfer testosterone. Documented cases of premature puberty in young children and virilization in female partners. The most clinically significant gel risk. Mitigation: apply to skin covered by clothing within 2 hours, wash hands immediately after application, shower 5+ hours post-application before close contact with others. For patients with young children, gel is often a poor format choice.
  • Application-site skin irritation (5-15%). Local redness, itching, occasional rash. Switching application site rotation often helps.
  • Variable absorption. Skin absorption varies by humidity, recent bathing, application technique, and individual skin characteristics. Testosterone levels can be inconsistent compared to injection. Lab monitoring is even more important on gel than on injection.
  • Cost (typically the brand-only premium). Brand AndroGel is $400-700/month cash-pay; insurance + savings card brings it to $30-150/month for eligible patients. Generic AndroGel exists but adoption is limited.

Patch-specific side effects (Androderm)

Transdermal testosterone patches add:

  • Application-site irritation (30-50% — the highest-friction format).Most-reported issue with patch TRT. Local redness, itching, sometimes blistering. Often improves with site rotation, OTC hydrocortisone before patch placement, and proper skin prep. About 10% of patch users discontinue specifically because of skin reactions.
  • Patch falling off. Sweat, swimming, heavy exercise can dislodge patches. Re-application or replacement patches needed.
  • Lower peak testosterone than injection. Patch typically produces total testosterone in the 400-700 ng/dL range — adequate for most patients but lower than the 700-900 range that injection often achieves.
  • No skin-transfer risk (unlike gel). The patch contains the testosterone in a controlled-release matrix — once applied, no skin-to-skin transfer to others.

Pellet-specific side effects (Testopel)

Subcutaneous testosterone pellets add:

  • Insertion-site issues. Small incision in upper buttock, local anesthesia. Bruising and soreness for 2-5 days post-procedure is typical. Rare cases of pellet extrusion (a pellet works its way back out through the incision) or insertion-site infection.
  • Dose-locking. Once pellets are inserted, the dose is locked for the implant duration (3-6 months). Side effects must be managed pharmacologically — AI for estradiol, phlebotomy for hematocrit — rather than by dose reduction. This is the biggest pellet downside for patients prone to side effects.
  • Variability across cycles. Number of pellets, insertion site, and individual absorption affect plasma levels. Some patients see a notable peak in the first 2-4 weeks post-insertion that tapers over the cycle.
  • Removal is impractical. Pellets are designed to dissolve gradually. Once inserted, they're not routinely removed. Severe side effects requiring discontinuation are managed by waiting for the cycle to taper.

Practical management decision tree

For common issues, the standard management approach:

  • Hematocrit climbing above 50%: Reduce dose 10-25%, recheck in 6 weeks. If stays elevated, consider switching from peak/trough injection to flatter formulation (twice-weekly, daily SubQ, or gel).
  • Hematocrit above 54%: Mandatory dose reduction. Consider therapeutic phlebotomy. If can't get hematocrit below 54%, consider pausing TRT.
  • Estradiol elevation with symptoms (water retention, mood, breast tenderness):First, confirm elevation with sensitive estradiol assay (regular E2 assay is unreliable in men). Then dose reduction or AI co-therapy (anastrozole 0.25-0.5mg twice weekly typical starting dose). Avoid over-suppression.
  • Mood/energy fluctuations on weekly injection: Switch to twice-weekly or daily SubQ. Most patients see marked improvement.
  • Severe gel application-site reaction or transfer concern: Switch to injection (cleanest no-transfer-risk option) or patch.
  • Persistent patch site irritation: Try OTC hydrocortisone, site rotation, alternative patch brands. If unresolved, switch to injection or gel.
  • PSA rising on TRT:If >1.4 ng/mL increase in 12 months or absolute >4.0 ng/mL, urology workup. PSA monitoring is non-negotiable for all TRT patients age 40+.
The systemic side-effect profile of TRT is roughly equivalent across formulations — testosterone is testosterone. Where formulations diverge is in delivery-specific issues: injection peak/trough, gel skin transfer, patch irritation, pellet dose-locking. Choose the format that minimizes the format-specific issue you're most likely to experience.

Frequently asked questions

What's the most common TRT side effect?

Polycythemia (elevated red blood cell count / hematocrit) is the most-reported side effect across all TRT formulations — affects 5-15% of patients. It's why quarterly hematocrit monitoring is non-negotiable. Managed with dose reduction, switching from peak/trough injection to more stable formulations (gel, daily injection), or therapeutic phlebotomy if hematocrit exceeds 54%. Acne, oily skin, and emotional fluctuations during dose-finding are also very common but typically resolve once protocol stabilizes.

Did the FDA actually remove the cardiovascular black-box warning?

Yes. In March 2025, the FDA formally removed the 2014 cardiovascular black-box warning from all testosterone product labeling, replacing it with a blood-pressure warning. The change followed the TRAVERSE trial (NEJM 2023), which demonstrated cardiovascular safety in middle-aged and older men with hypogonadism. The label change resolved the over-cautious prescribing pattern that had developed under the original warning. Cardiovascular safety monitoring (lipid panel quarterly) remains standard of care, but the catastrophic-risk framing of the 2014-2024 era is no longer FDA's position.

Why do injectable TRT users sometimes report mood swings?

Weekly cypionate at 200mg+ produces a peak-and-trough plasma curve — testosterone peaks 24-72 hours post-injection, troughs by day 7. Some patients experience mood/energy fluctuations tied to the curve. The fix: split the weekly dose into twice-weekly (Mon/Thu canonical schedule) at 100mg each, which flattens the curve. Some patients prefer daily subcutaneous (10-30mg/day) for the smoothest curve. Gel formulations also produce smooth daily levels but at higher cost.

Is gel transfer to family members really a risk?

Yes — this is a black-box warning that DID survive the FDA's March 2025 label changes. Skin-to-skin contact between a gel-applying patient and a partner, child, or pet can transfer testosterone. Documented cases of premature puberty in young children and virilization in female partners. The mitigation: apply gel to skin that's covered by clothing within 2 hours, wash hands immediately after application, shower 5+ hours post-application before close contact. For patients with young children, gel is often a poor format choice — injection or patch eliminates the transfer risk.

How quickly should hematocrit be checked on TRT?

Baseline (before TRT), 6-8 weeks after starting, then quarterly thereafter. Some clinicians monitor more frequently in the first 6 months while protocol stabilizes. If hematocrit climbs above 50%, dose reduction or formulation change is the typical first move. Above 52%, more aggressive intervention; above 54%, mandatory dose reduction + therapeutic phlebotomy if patient stays on TRT. Hematocrit monitoring is the single most important ongoing safety check for all TRT patients regardless of formulation.

What about prostate-related side effects?

Baseline PSA before TRT; quarterly PSA monitoring during therapy. The TRAVERSE trial confirmed TRT does not cause new prostate cancer in men with normal baseline PSA. PSA elevation during TRT (>1.4 ng/mL increase from baseline in any 12-month period, or absolute >4.0 ng/mL) warrants urology workup. BPH (benign prostatic hyperplasia) symptoms can worsen on TRT — patients with significant baseline urinary symptoms may need urology evaluation before starting. Absolute contraindication: known active prostate cancer.

Are pellet side effects different from injection?

Same systemic side effects (polycythemia, acne, mood, prostate effects, lipid changes) at properly-dosed steady state. Pellet adds insertion-site issues: bruising, soreness for 2-5 days post-procedure, rare cases of pellet extrusion (where a pellet works its way back out through the incision), rare insertion-site infection. The bigger pellet-specific issue is dose-locking: if you develop a side effect (high estradiol, elevated hematocrit), you can't easily reduce the dose mid-cycle the way you can with injection. Side effects on pellet are managed pharmacologically (AI for estradiol, phlebotomy for hematocrit) rather than by dose reduction.

Also see